These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report. Iannetti L; Abbouda A; Fabiani C; Zito R; Campanella M J Med Case Rep; 2013 Jul; 7():199. PubMed ID: 23889894 [TBL] [Abstract][Full Text] [Related]
4. Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Al-Debasi T; Al-Bekairy A; Al-Katheri A; Al Harbi S; Mansour M Saudi J Ophthalmol; 2017; 31(2):99-105. PubMed ID: 28559722 [TBL] [Abstract][Full Text] [Related]
5. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects. Su W; Li Z; Li Y; Lin M; Yao L; Liu Y; He Z; Wu C; Liang D Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9108-15. PubMed ID: 22039247 [TBL] [Abstract][Full Text] [Related]
6. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization. Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164 [TBL] [Abstract][Full Text] [Related]
7. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709 [TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. You IC; Im SK; Lee SH; Yoon KC Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729 [TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic effect of KR-31831 on corneal and choroidal neovascularization in rat models. Kim IT; Park HY; Choi JS; Joo CK Invest Ophthalmol Vis Sci; 2012 May; 53(6):3111-9. PubMed ID: 22491414 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model. Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169 [TBL] [Abstract][Full Text] [Related]
13. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570 [TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits. Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293 [TBL] [Abstract][Full Text] [Related]